In November of 2009, Dr. Goldknopf was the Keynote speaker and Session Chair of the session entitled “Biomarkers and Diagnostics in Personalized Medicine” at the BIT International Congress and Exposition of Molecular Diagnostics (ICEMD 2009) meeting in Beijing, China.
Presently, through our collaboration with Transgenomic, Inc. the company is preparing to commercialize the Alzheimer’s disease diagnostic test and the Parkinson’s disease diagnostic test in Transgenomic’s CLIA certified lab in the first quarter of 2010, from which Power3 will receive milestone payments and Royalties. Power3 in 2009 had revenues of over $200,000 which included the license fee and operations support from Transgenomic, Inc.
The management of Power3 Medical Products, Inc. wishes to thank the many shareholders, investors and vendors who stepped up to the plate to provide Power3 the means to continue its mission to provide the world with new and better tools for the understanding and diagnostics of diseases to fulfill critical unmet needs. The management has worked exceedingly hard to sustain our progress during this economic down turn. We will continue to serve to the best of our ability for the science, the future of the company, and the shareholders. We feel blessed to be in this industry.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.